News & Updates
Filter by Specialty:
Does atezolizumab improve OS in patients with resected NSCLC and PD-L1 ≥1 percent?
16 Oct 2022
byRoshini Claire Anthony
The first interim analysis of the phase III IMpower010 trial suggests an overall survival (OS) benefit with atezolizumab compared with best supportive care (BSC) in patients with resected non-small cell lung cancer (NSCLC) with PD-L1* tumour cell expression ≥1 percent.
Does atezolizumab improve OS in patients with resected NSCLC and PD-L1 ≥1 percent?
16 Oct 2022
Pemetrexed-based chemo boosts survival in NSCLC
15 Oct 2022
As an add-on to gefitinib monotherapy, pemetrexed-based chemotherapy improves survival outcomes in nonsmall cell lung cancer (NSCLC) patients harbouring EGFR mutations, a recent study has found.
Pemetrexed-based chemo boosts survival in NSCLC
15 Oct 2022
Metformin, ivermectin, fluvoxamine OUT for severe COVID-19 prevention?
11 Oct 2022
byRoshini Claire Anthony
The use of metformin, fluvoxamine, or ivermectin in an outpatient setting did not appear to prevent progression to severe COVID-19, according to results of the phase III COVID-OUT trial.
